CY1115278T1 - Παραγωγα 2-αρυλιμιδαζολης ως αναστολεις του ενζυμου ρdε10α - Google Patents
Παραγωγα 2-αρυλιμιδαζολης ως αναστολεις του ενζυμου ρdε10αInfo
- Publication number
- CY1115278T1 CY1115278T1 CY20141100539T CY141100539T CY1115278T1 CY 1115278 T1 CY1115278 T1 CY 1115278T1 CY 20141100539 T CY20141100539 T CY 20141100539T CY 141100539 T CY141100539 T CY 141100539T CY 1115278 T1 CY1115278 T1 CY 1115278T1
- Authority
- CY
- Cyprus
- Prior art keywords
- subject
- compound
- formula
- effective amount
- therapeutically effective
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Αυτή η εφεύρεση απευθύνεται σε ενώσεις, οι οποίες είναι αναστολείς του ενζύμου ΡDE10A. Η εφεύρεση παρέχει μια φαρμακευτική σύνθεση περιλαμβάνοντας μια θεραπευτικώς αποτελεσματική ποσότητα μιας ένωσης της εφεύρεσης και μια φαρμακευτικώς αποδεκτή ουσία-φορέας. Η παρούσα εφεύρεση παρέχει επίσης και διεργασίες για την παρασκευή των ενώσεων του χημικού τύπου (Ι). Η παρούσα εφεύρεση παρέχει περαιτέρω μια μέθοδο αγωγής ενός υποκειμένου υποφέροντας από μία νευροεκφυλιστική διαταραχή περιλαμβάνοντας την χορήγηση στο υποκείμενο μίας θεραπευτικώς αποτελεσματικής ποσότητας μιας ένωσης του χημικού τύπου (Ι). Η παρούσα εφεύρεση παρέχει επίσης και μία μέθοδο αγωγής ενός υποκειμένου υποφέροντας από έναν εθισμό σε φάρμακα περιλαμβάνοντας την χορήγηση στο υποκείμενο μιας θεραπευτικώς αποτελεσματικής ποσότητας μιας ένωσης του χημικού τύπου (Ι). Η παρούσα εφεύρεση παρέχει περαιτέρω μια μέθοδο αγωγής ενός υποκειμένου υποφέροντας από μία ψυχιατρική διαταραχή περιλαμβάνοντας την χορήγηση στο υποκείμενο μιας θεραπευτικώς αποτελεσματικής ποσότητας μιας ένωσης του χημικού τύπου (Ι).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28732409A | 2009-12-17 | 2009-12-17 | |
DKPA200901341 | 2009-12-17 | ||
EP10797990.8A EP2513105B1 (en) | 2009-12-17 | 2010-12-15 | 2-arylimidazole derivatives as pde10a enzyme inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1115278T1 true CY1115278T1 (el) | 2017-01-04 |
Family
ID=44246810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100539T CY1115278T1 (el) | 2009-12-17 | 2014-07-18 | Παραγωγα 2-αρυλιμιδαζολης ως αναστολεις του ενζυμου ρdε10α |
Country Status (34)
Country | Link |
---|---|
US (2) | US8501797B2 (el) |
EP (1) | EP2513105B1 (el) |
JP (1) | JP5698761B2 (el) |
KR (1) | KR101777889B1 (el) |
CN (1) | CN102753551B (el) |
AR (1) | AR079498A1 (el) |
AU (1) | AU2010333437B2 (el) |
CA (1) | CA2783727C (el) |
CO (1) | CO6612246A2 (el) |
CR (1) | CR20120317A (el) |
CY (1) | CY1115278T1 (el) |
DK (1) | DK2513105T3 (el) |
DO (1) | DOP2012000168A (el) |
EA (1) | EA021415B1 (el) |
ES (1) | ES2484692T3 (el) |
GE (1) | GEP20156242B (el) |
GT (1) | GT201200180A (el) |
HK (1) | HK1177739A1 (el) |
HR (1) | HRP20140632T1 (el) |
MA (1) | MA33924B1 (el) |
MX (1) | MX2012007144A (el) |
MY (1) | MY158202A (el) |
NZ (1) | NZ600416A (el) |
PL (1) | PL2513105T3 (el) |
PT (1) | PT2513105E (el) |
RS (1) | RS53413B (el) |
SG (1) | SG181536A1 (el) |
SI (1) | SI2513105T1 (el) |
SM (1) | SMT201400114B (el) |
TN (1) | TN2012000287A1 (el) |
TW (1) | TWI481607B (el) |
UA (1) | UA107817C2 (el) |
WO (1) | WO2011072696A1 (el) |
ZA (1) | ZA201204418B (el) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑的2-芳基咪唑衍生物 |
TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之雜芳香族苯基咪唑衍生物 |
TWI487705B (zh) | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之雜芳香族芳基三唑衍生物 |
JO3089B1 (ar) * | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
LT2651902T (lt) | 2010-12-17 | 2018-01-10 | Reata Pharmaceuticals, Inc. | Tricikliniai pirazolil- ir pirimidinilenonai, kaip antioksidantų uždegimo moduliatoriai |
JP5916752B2 (ja) | 2010-12-17 | 2016-05-11 | ノバルティス アーゲー | 5−クロロ−n2−(2−イソプロポキシ−5−メチル−4−ピペリジン−4−イル−フェニル)−n4[2−(プロパン−2−スルホニル)−フェニル]−ピリミジン−2,4−ジアミンの結晶形 |
WO2012096929A2 (en) | 2011-01-11 | 2012-07-19 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
WO2012112946A1 (en) | 2011-02-18 | 2012-08-23 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
US9938269B2 (en) * | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
CA2845578C (en) * | 2011-08-25 | 2016-02-16 | Merck Sharp & Dohme Corp. | Pyrimidine pde10 inhibitors |
AR089361A1 (es) | 2011-12-21 | 2014-08-20 | Lundbeck & Co As H | Derivados de quinolina como inhibidores de la enzima pde10a |
WO2013107856A1 (en) * | 2012-01-20 | 2013-07-25 | H. Lundbeck A/S | Imidazole derivatives as pde10a enzyme inhibitors |
WO2013127817A1 (en) | 2012-02-27 | 2013-09-06 | H. Lundbeck A/S | Imidazole derivatives as pde10a enzyme inhibitors |
WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
JP7076441B2 (ja) * | 2016-11-02 | 2022-05-27 | ヤンセン ファーマシューティカ エヌ.ベー. | PDE2阻害剤としての[1,2,4]トリアゾロ[1,5-a]ピリミジン誘導体 |
GB202002926D0 (en) * | 2020-02-28 | 2020-04-15 | Benevolentai Tech Limited | Compositions and uses thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8307865D0 (en) | 1983-03-22 | 1983-04-27 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
US5571775A (en) | 1994-07-11 | 1996-11-05 | Dowelanco | N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides |
US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
IL149106A0 (en) | 2001-04-20 | 2002-11-10 | Pfizer Prod Inc | Therapeutic use of selective pde10 inhibitors |
FR2824065A1 (fr) | 2001-04-26 | 2002-10-31 | Neuro3D | Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations |
AU2003259068B2 (en) * | 2002-08-09 | 2009-07-02 | Astrazeneca Ab | "1,2,4"oxadiazoles as modulators of metabotropic glutamate receptor-5 |
JP2006509832A (ja) | 2002-10-30 | 2006-03-23 | ニューロ3デー | サイクリックヌクレオチドホスホジエステラーゼ阻害剤、その調製及び使用 |
MXPA05013822A (es) | 2003-06-30 | 2006-02-28 | Altana Pharma Ag | Pirrolodihidroisoquinolinas utiles en el tratamiento del cancer. |
CA2530114A1 (en) | 2003-06-30 | 2005-01-13 | Altana Pharma Ag | Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
US20070032404A1 (en) | 2003-07-31 | 2007-02-08 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
WO2005014588A1 (en) | 2003-08-01 | 2005-02-17 | Argenta Discovery Limited | Substituted thienyl-hydroxamic acids having histone deacetylase activity |
CA2556413A1 (en) | 2004-02-18 | 2005-09-09 | Pfizer Products Inc. | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline |
FR2870539B1 (fr) | 2004-05-19 | 2006-08-04 | Greenpharma Sa Sa | Nouvelles methodes et medicaments |
EP1755611A1 (en) | 2004-06-07 | 2007-02-28 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
US20060160814A1 (en) | 2004-09-03 | 2006-07-20 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
US20090176829A1 (en) * | 2006-05-02 | 2009-07-09 | Pfizer Inc | Bicyclic heteroaryl compounds as pde10 inhibitors |
US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
JP2009542732A (ja) * | 2006-07-10 | 2009-12-03 | ハー・ルンドベック・アクチエゼルスカベット | 6,7−ジアルコキシキナゾリン、6,7−ジアルコキシフタラジンおよび6,7−ジアルコキシイソキノリンの(3−アリール−ピペラジン−1−イル)、(2−アリール−モルホリン−4−イル)および(2−アリール−チオモルホリン−4−イル)誘導体 |
CA2692713A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Heterocyclic modulators of pkb |
TWI501965B (zh) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之新穎苯基咪唑衍生物 |
TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之雜芳香族苯基咪唑衍生物 |
TWI487705B (zh) * | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之雜芳香族芳基三唑衍生物 |
TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑的2-芳基咪唑衍生物 |
-
2010
- 2010-12-14 TW TW099143693A patent/TWI481607B/zh not_active IP Right Cessation
- 2010-12-15 EA EA201290518A patent/EA021415B1/ru not_active IP Right Cessation
- 2010-12-15 KR KR1020127015565A patent/KR101777889B1/ko active IP Right Grant
- 2010-12-15 PL PL10797990T patent/PL2513105T3/pl unknown
- 2010-12-15 MY MYPI2012002597A patent/MY158202A/en unknown
- 2010-12-15 EP EP10797990.8A patent/EP2513105B1/en active Active
- 2010-12-15 DK DK10797990.8T patent/DK2513105T3/da active
- 2010-12-15 US US13/515,325 patent/US8501797B2/en not_active Expired - Fee Related
- 2010-12-15 ES ES10797990.8T patent/ES2484692T3/es active Active
- 2010-12-15 SI SI201030671T patent/SI2513105T1/sl unknown
- 2010-12-15 AU AU2010333437A patent/AU2010333437B2/en not_active Ceased
- 2010-12-15 MA MA35065A patent/MA33924B1/fr unknown
- 2010-12-15 PT PT107979908T patent/PT2513105E/pt unknown
- 2010-12-15 CN CN201080064084.5A patent/CN102753551B/zh not_active Expired - Fee Related
- 2010-12-15 SG SG2012041547A patent/SG181536A1/en unknown
- 2010-12-15 WO PCT/DK2010/050343 patent/WO2011072696A1/en active Application Filing
- 2010-12-15 JP JP2012543476A patent/JP5698761B2/ja not_active Expired - Fee Related
- 2010-12-15 CA CA2783727A patent/CA2783727C/en not_active Expired - Fee Related
- 2010-12-15 RS RS20140371A patent/RS53413B/en unknown
- 2010-12-15 MX MX2012007144A patent/MX2012007144A/es active IP Right Grant
- 2010-12-15 GE GEAP201012787A patent/GEP20156242B/en unknown
- 2010-12-15 NZ NZ600416A patent/NZ600416A/xx not_active IP Right Cessation
- 2010-12-15 UA UAA201207978A patent/UA107817C2/uk unknown
- 2010-12-16 AR ARP100104671A patent/AR079498A1/es unknown
-
2012
- 2012-06-05 TN TNP2012000287A patent/TN2012000287A1/en unknown
- 2012-06-07 GT GT201200180A patent/GT201200180A/es unknown
- 2012-06-12 CR CR20120317A patent/CR20120317A/es unknown
- 2012-06-15 ZA ZA2012/04418A patent/ZA201204418B/en unknown
- 2012-06-15 CO CO12101119A patent/CO6612246A2/es active IP Right Grant
- 2012-06-15 DO DO2012000168A patent/DOP2012000168A/es unknown
-
2013
- 2013-04-22 HK HK13104851.5A patent/HK1177739A1/xx not_active IP Right Cessation
- 2013-06-24 US US13/924,712 patent/US8927738B2/en not_active Expired - Fee Related
-
2014
- 2014-07-02 HR HRP20140632AT patent/HRP20140632T1/hr unknown
- 2014-07-18 CY CY20141100539T patent/CY1115278T1/el unknown
- 2014-08-18 SM SM201400114T patent/SMT201400114B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1115278T1 (el) | Παραγωγα 2-αρυλιμιδαζολης ως αναστολεις του ενζυμου ρdε10α | |
CY1115843T1 (el) | Ετεροαρωματικες ενωσεις φαινυλιμιδαζολιου ως αναστολεις ενζυμου pde10a | |
CY1115001T1 (el) | Νεα παραγωγα φαινυλιμιδαζολιου ως αναστολεις ενζυμου pde10a | |
CY1116361T1 (el) | Ετεροαρωματικα αρυλο τριαζολικα παραγωγα ως αναστολεις pde10a ενζυμου | |
IN2015DN02829A (el) | ||
UA102693C2 (ru) | Производные фенилимидазола как ингибиторы фермента pde10a | |
PH12014501695B1 (en) | Pde9 inhibitors with imidazo triazinone backbone | |
JO3089B1 (ar) | مشتقات ايميدازول كمثبطات لانزيمات pde10a | |
CY1116689T1 (el) | Παραγωγα ιμιδαζολης ως αναστολεις του ενζυμου pde10a | |
MX336915B (es) | Derivados de imidazol como inhibidores de la enzima pde10a. | |
TN2013000200A1 (en) | Imidazole derivatives as pde 10a enzyme inhibitors |